What are the top ten targets for blood cancer/solid tumors? Cancer Cell Therapy In-depth Inventory

The Annual Meeting of the American Society of Clinical Oncology (ASCO) will open over the weekend, and the latest developments in cancer cell therapy as part of a major breakthrough in cancer treatment will be presented at the ASCO annual meetingThe initial clinical results of Allogene's "use-only" allogeneic CAR-T therapy, as well as the clinical results of THE CAR-T developed by Nanjing Legend and Jansen co-development of BCMA, received wideattention when the summary of the asco annual meeting was announcedHow hot is the cancer cell therapy for all osteogenics? How has cell therapy progressed in targeting solid tumors? Researchers at the Cancer Research Institute in New York have published an in-depth review of the breakthrough field of cancer cell therapy in an in-depth review published in Nature Reviews Drug DiscoveryThe progress of research and development in this area was compared with that of the previous yearToday the potion Kant content team will introduce the highlights of thisThere are currently 1,483 active therapies in the global cancer cell therapy pipeline, an increase of 472 compared to last yearCar-T cell therapy grew the most, with 290 new therapies (up 51 percent) compared to last yearThe biggest increase was in innovative T-cell therapies, including CRISPR gene-edited T-cells or gamma-t-cell therapy, which increased from 59 last year to 108 this year (up 83 percent)Other types of cell therapies( including macrophages-based therapies) also increased significantly, with an increase of 56 treatments (46%)To further understand the development trends in the field of cancer cell therapy, the authors divide cell therapy into both hosoid alsometherapy and allogeneic (i.e.gtype) cell therapyStatistics show that although most of the experimental therapy in the study of cell is still autologous therapy, but pre-clinical and phase 1 clinical development stage of the largest increase in allogeneic therapies, respectively, 73.8% and 90.9%In the case of blood cancer, the most popular target is still CD19, which is the primary target for the treatment of B-cell blood cancerBut the two biggest targets for the increase were B-cell maturation antigens (BCMA) and CD22, both of which nearly doubled in number compared with the previous yearBCMA and CD22 are antigens expressed on the surface of B cellsCell therapy targeting these two targets can be used to treat Patients with B-cell blood cancers that are resistant to cell therapy targeted at CD19In terms of solid tumors, the largest number of categories are target sedations that have not yet been publishedAmong the published targets, cell therapy targeting GPC3 and prostate-specific membrane antigens (PSMA) increased the most, reaching 129% and 83%, respectivelyGPC3 is a acetylsulphate heparin protein polysaccharide (HSPG) that is highly expressed in a variety of pediatric embryonic solid tumors, including most hepatoblastomas, transverse fibroids, Wilms tumors (a type of pediatric kidney cancer) and so onIt is also an important biomarker of hepatocellular carcinomaPSMA is associated with prostate cancerTo measure progress in clinical development of cell therapy, researchers counted clinical trials of cancer cell therapy that have published trial results, according to GlobalData's clinical trial databaseStatistics show that in Phase 1 and Phase 2 clinical trials, most of the trials in which the results were published reached the main clinical endpoint of the trial, and the negative results were reported with littleIt is important to note that tumor-immersed lymphocyte therapy or natural killer cell therapy have reported positive clinical results in Both Phase 1 or 2 clinical trials for the treatment of solid tumorsOther types of cell therapy, such as cytokine-induced killer cells, have received positive results in Phase 3 or 4 clinical trialsBut the researchers also point out that failed clinical trials may not publish results, which affects the statisticsThe United States and China ranked first in the development of cancer cell therapy, according to researchersAs of March 2020, there are 600 therapies under development in the United States, compared with 508 in ChinaIn the United States, most cell therapies are developed by pharmaceutical companiesIn China, most of the development of cell therapies has been done in academic research institutions in the past, but last year, for the first time, the number of cell therapies developed by pharmaceutical companies exceeded the number developed by academic institutionsFrom 2019 to 2020, the number of preclinical cell therapies in China increased from 69 to 202China's Phase 1 and Phase 2 clinically developed cancer cell therapy programs are also growing at a rate of about 50% per yearPreclinical and clinical development in the field of cancer cell therapy is still expanding This area is intensifying the exploration of the application of "ready-to-use" therapies to a wider patient population Current early clinical results show the promise of such innovative treatments, but they still need time and more clinical trial data to verify that their efficacy is comparable to that of an ethogenic cell therapy China continues to develop innovative cell therapies, with a significant increase in its preclinical development programoverover over the past year and a world leader in clinical trials of oncology cell therapy The shift of major development activities from academic institutions to the pharmaceutical industry may further enhance the rigour of research (Original title: Deep inventory of cancer cell therapy, what are the top ten targets for blood cancer/solid tumors?) )